Audited Financial Results and recommendation of final dividend for financial year 2025-26
NEULANDLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.2 pts less than Nifty Smallcap 250 and 2.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Neuland Laboratories reported strong full-year results for FY 2025-26. Consolidated revenue grew 37% to Rs 2,02,299 lakhs from Rs 1,47,684 lakhs the prior year, driven by robust growth across Europe and the US. PAT surged approximately 40% to Rs 36,400 lakhs from Rs 26,011 lakhs, while EPS stood at Rs 283.71 (consolidated). The Board recommended a final dividend of Rs 34 per share (340%). An exceptional gain of Rs 7,640.36 lakhs from the transfer of an investment property was recorded in the prior year and excluded from ongoing earnings. The company also announced a Rs 143.4 crore capacity expansion at its Unit 1 to be funded through internal accruals and borrowings, with utilisation already at 91%. Statutory auditors MSKA & Associates LLP issued an unmodified (clean) opinion on both standalone and consolidated results. Dr. Mauricio Futran was appointed as an Additional Director (Non-Executive, Non-Independent).
Strong top-line and bottom-line growth with clean audit opinion and a healthy dividend payout signal positive sentiment for investors. The capacity expansion indicates management confidence in sustained demand growth, particularly from export markets.